James oversees CCAB’s preclinical development efforts and manages production teams focused on antibody production related to therapeutic, diagnostic and research tool development.
He brings over 15 years of experience in biotechnology and pharmaceutical discovery and development having held various research and management positions in both industry and academia, including Genentech, Affinium Pharmaceuticals, Princess Margaret Hospital/University Health Network, and most recently at the Toronto Recombinant Antibody Centre.
Previously, James has led drug discovery teams and was instrumental in discovering and advancing multiple preclinical drug candidates towards the clinic. He is known for the discovery of TRAIL receptors and has deep knowledge in oncology and extensive experience in antibody discovery and development, animal models and pharmacology. James holds Doctoral and Masters degrees from the University of Toronto and obtained his postdoctoral training at both University of Toronto and University of Michigan.